Clinical Trials Browser

INDUSTRY × Plasmacytoma × daratumumab × Clear all

NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

498 enrolled 15 charts

Multiple Myeloma, Plasmacytoma

NCT01946477 2025-06-06

POM MM 014

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasmacytoma